On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Alkem Laboratories has increased 17.17% to Rs 4000.99 crore. Operating profit margin has jumped from 22.05% to 23.01%, leading to 22.31% rise in operating profit to Rs 920.77 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 26.03% to 22.77%. Purchase of finished goods cost rose from 10.21% to 11.86%. Employee cost increased from 17.61% to 17.86%. Other expenses fell from 24.43% to 24.36%. Other income fell 22.90% to Rs 103.69 crore. PBIDT rose 15.46% to Rs 1024.46 crore. Provision for interest rose 24.45% to Rs 35.02 crore. Loan funds rose to Rs 2,355.60 crore as of 30 September 2025 from Rs 1,477.90 crore as of 30 September 2024. Inventories rose to Rs 3,007.36 crore as of 30 September 2025 from Rs 2,912.18 crore as of 30 September 2024. Sundry debtors were higher at Rs 3,091.52 crore as of 30 September 2025 compared to Rs 2,498.11 crore as of 30 September 2024. Cash and bank balance declined from Rs 1,952.25 crore as of 30 September 2024 to Rs 1,547.65 crore as of 30 September 2025. Investments rose to Rs 2,533.16 crore as of 30 September 2025 from Rs 1,160.06 crore as of 30 September 2024 . PBDT rose 15.16% to Rs 989.44 crore. Provision for depreciation rose 18.63% to Rs 93.61 crore. Fixed assets increased to Rs 3,138.10 crore as of 30 September 2025 from Rs 2,561.16 crore as of 30 September 2024. Intangible assets increased from Rs 537.36 crore to Rs 833.68 crore. Profit before tax grew 14.81% to Rs 895.83 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 116.23 crore, compared to Rs 78.3 crore. Effective tax rate was 12.98% compared to 10.04%. Minority interest increased 5.48% to Rs 14.05 crore. Net profit attributable to owners of the company increased 11.10% to Rs 765.06 crore. Equity capital stood at Rs 23.91 crore as of 30 September 2025 to Rs 23.91 crore as of 30 September 2024. Per share face Value remained same at Rs 2.00. Promoters’ stake was 51.20% as of 30 September 2025 ,compared to 55.66% as of 30 September 2024 .
For year-to-date (YTD) results analysis.
Net sales (including other operating income) of Alkem Laboratories has increased 14.36% to Rs 7372.13 crore. Operating profit margin has jumped from 21.12% to 22.51%, leading to 21.91% rise in operating profit to Rs 1,659.82 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 26.19% to 23.41%. Purchase of finished goods cost rose from 11.09% to 11.74%. Employee cost increased from 18.26% to 18.96%. Other expenses fell from 23.96% to 23.46%. Other income fell 5.73% to Rs 240.18 crore. PBIDT rose 17.56% to Rs 1900 crore. Provision for interest rose 13.19% to Rs 64.8 crore. Loan funds rose to Rs 2,355.60 crore as of 30 September 2025 from Rs 1,477.90 crore as of 30 September 2024. Inventories rose to Rs 3,007.36 crore as of 30 September 2025 from Rs 2,912.18 crore as of 30 September 2024. Sundry debtors were higher at Rs 3,091.52 crore as of 30 September 2025 compared to Rs 2,498.11 crore as of 30 September 2024. Cash and bank balance declined from Rs 1,952.25 crore as of 30 September 2024 to Rs 1,547.65 crore as of 30 September 2025. Investments rose to Rs 2,533.16 crore as of 30 September 2025 from Rs 1,160.06 crore as of 30 September 2024 . PBDT rose 17.72% to Rs 1835.2 crore. Provision for depreciation rose 13.74% to Rs 181.29 crore. Fixed assets increased to Rs 3,138.10 crore as of 30 September 2025 from Rs 2,561.16 crore as of 30 September 2024. Intangible assets increased from Rs 537.36 crore to Rs 833.68 crore. Profit before tax grew 18.17% to Rs 1,653.91 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 218.92 crore, compared to Rs 147.42 crore. Effective tax rate was 13.14% compared to 10.53%.Minority interest decreased 3.80% to Rs 17.70 crore. Net profit attributable to owners of the company increased 15.85% to Rs 1,429.32 crore. Equity capital stood at Rs 23.91 crore as of 30 September 2025 to Rs 23.91 crore as of 30 September 2024. Per share face Value remained same at Rs 2.00. Promoters’ stake was 51.20% as of 30 September 2025 ,compared to 55.66% as of 30 September 2024 .
Full year results analysis.
Net sales (including other operating income) of Alkem Laboratories has increased 2.34% to Rs 12964.52 crore. Operating profit margin has jumped from 17.73% to 19.38%, leading to 11.88% rise in operating profit to Rs 2,512.15 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 26.04% to 26.15%. Purchase of finished goods cost fell from 12.87% to 11.51%. Employee cost increased from 17.39% to 18.65%. Other expenses fell from 25.95% to 24.59%. Other income rose 58.84% to Rs 493.74 crore. PBIDT rose 17.59% to Rs 3005.89 crore. Provision for interest rose 8.26% to Rs 121.7 crore. Loan funds declined from Rs 1,418.41 crore as of 31 March 2024 to Rs 1,380.90 crore as of 31 March 2025. Inventories rose to Rs 2,922.41 crore as of 31 March 2025 from Rs 2,661.18 crore as of 31 March 2024. Sundry debtors were higher at Rs 2,466.25 crore as of 31 March 2025 compared to Rs 2,252.81 crore as of 31 March 2024. Cash and bank balance declined from Rs 1,579.35 crore as of 31 March 2024 to Rs 1,563.08 crore as of 31 March 2025. Investments rose to Rs 1,845.50 crore as of 31 March 2025 from Rs 483.78 crore as of 31 March 2024 . PBDT rose 18.01% to Rs 2884.19 crore. Provision for depreciation rose 19.33% to Rs 357.16 crore. Fixed assets increased to Rs 2,977.27 crore as of 31 March 2025 from Rs 2,614.61 crore as of 31 March 2024. Intangible assets increased from Rs 416.74 crore to Rs 423.11 crore. Profit before tax grew 17.83% to Rs 2,527.03 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 311.03 crore, compared to Rs 211.67 crore. Effective tax rate was 12.31% compared to 10.46%. Minority interest increased 218.04% to Rs 49.90 crore. Net profit attributable to owners of the company increased 20.59% to Rs 2,165.48 crore. Equity capital stood at Rs 23.91 crore as of 31 March 2025 to Rs 23.91 crore as of 31 March 2024. Per share face Value remained same at Rs 2.00. Promoters’ stake was 55.13% as of 31 March 2025 ,compared to 56.74% as of 31 March 2024 . Cash flow from operating activities decreased to Rs 1,912.84 crore for year ended March 2025 from Rs 1,948.07 crore for year ended March 2024. Cash flow used in acquiring fixed assets during the year ended March 2025 stood at Rs 675.62 crore, compared to Rs 259.29 crore during the year ended March 2024. Other Highlights
In
Q2 FY26, India sales increased 12.4% YoY and International sales grew 29.5%
YoY. Non-US business revenue grew by 32.4% YoY.
US business sales contributed 19.3% to
total sales in Q2 FY26.
During Q2 FY26, for the US market, the
Company filed 02 ANDAs, received 01 ANDA tentative approvals and launched 04
products.
In terms of key therapy segment
performance, the anti-diabetic segment grew by 6.8% YoY in Q2 FY26,
anti-infectives grew by 4.8%, derma grew 5.3%, gastrointestinal grew by 2.2%, neuro/CNS
by 5%, pain/analgesics grew 9.6%, respiratory grew 19.9%, and VMN grew 13.8%.
R&D
expenses for Q2 FY26 was Rs 130.2 crore representing 3.3% of total revenue from
operations.
Management Comments :
Dr
Vikas Gupta, CEO, Alkem said, “Q2 FY26 has been another strong quarter for us,
marked by robust growth across India, the US, and key international markets. We
also saw healthy traction in new product launches across markets. The GST
revision is a positive step, and we adapted swiftly to ensure a seamless
transition. Our improved gross margins and operating leverage have contributed
to a stronger EBITDA profile. As we look ahead, we remain focused on
accelerating growth and continue to strengthen our presence in key markets.”
| Alkem Laboratories : Consolidated Results | | | Quarter ended | Year to Date | Year ended |
|---|
| Particulars | 202509 | 202409 | Var.(%) | 202509 | 202409 | Var.(%) | 202503 | 202403 | Var.(%) |
|---|
| Net Sales (including other operating income) | 4,000.99 | 3,414.67 | 17.17 | 7,372.13 | 6,446.49 | 14.36 | 12,964.52 | 12,667.58 | 2.34 | | OPM (%) | 23.01 | 22.05 | 97 bps | 22.51 | 21.12 | 140 bps | 19.38 | 17.73 | 165 bps | | OP | 920.77 | 752.83 | 22.31 | 1,659.82 | 1,361.47 | 21.91 | 2,512.15 | 2,245.49 | 11.88 | | Other Inc. | 103.69 | 134.48 | -22.90 | 240.18 | 254.79 | -5.73 | 493.74 | 310.84 | 58.84 | | PBIDT | 1,024.46 | 887.31 | 15.46 | 1,900.00 | 1,616.26 | 17.56 | 3,005.89 | 2,556.33 | 17.59 | | Interest | 35.02 | 28.14 | 24.45 | 64.80 | 57.25 | 13.19 | 121.70 | 112.41 | 8.26 | | PBDT | 989.44 | 859.17 | 15.16 | 1,835.20 | 1,559.01 | 17.72 | 2,884.19 | 2,443.92 | 18.01 | | Depreciation | 93.61 | 78.91 | 18.63 | 181.29 | 159.39 | 13.74 | 357.16 | 299.3 | 19.33 | | PBT | 895.83 | 780.26 | 14.81 | 1653.91 | 1399.62 | 18.17 | 2527.03 | 2144.62 | 17.83 | | Share of Profit/(Loss) from Associates | -0.49 | 0 | - | -0.9 | 0 | - | -0.62 | 0 | - | | PBT before EO | 895.34 | 780.26 | 14.75 | 1653.01 | 1399.62 | 18.10 | 2526.41 | 2144.62 | 17.80 | | EO Income | 0 | 0 | - | 12.93 | 0 | - | 0 | -121.49 | - | | PBT after EO | 895.34 | 780.26 | 14.75 | 1665.94 | 1399.62 | 19.03 | 2526.41 | 2023.13 | 24.88 | | Taxation | 116.23 | 78.3 | 48.44 | 218.92 | 147.42 | 48.50 | 311.03 | 211.67 | 46.94 | | PAT | 779.11 | 701.96 | 10.99 | 1447.02 | 1252.2 | 15.56 | 2215.38 | 1811.46 | 22.30 | | Minority Interest (MI) | 14.05 | 13.32 | 5.48 | 17.7 | 18.4 | -3.80 | 49.9 | 15.69 | 218.04 | | Net profit | 765.06 | 688.64 | 11.10 | 1429.32 | 1233.8 | 15.85 | 2165.48 | 1795.77 | 20.59 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 765.06 | 688.64 | 11.10 | 1429.32 | 1233.8 | 15.85 | 2165.48 | 1795.77 | 20.59 | | EPS (Rs)* | 63.99 | 57.60 | 11.10 | 118.62 | 103.19 | 14.95 | 181.11 | 159.21 | 13.76 | | | * EPS is on current equity of Rs 23.91 crore, Face value of Rs 2, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|